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Introduction
L a n g e r h a n s  C e l l  H i s t i o c y t o s i s  ( LCH) is a rare
disease with unknown etiology. The incidence of LCH
is estimated to be 0.2-0.5 cases per 100.000 per year. Bone
is the most frequent site of this disease. It is usually
considered to be a disease of childhood. Many patients
are 1-15 years old, however the diagnosis frequently is
made in adults and many cases of childhood onset
progress into adult life. LCH has a widely variable disease
course and clinical presentation with the capacity for
spontaneous remission or chronic disease. There is
persistent controversy surrounding the terminology of
histiocytic disorders. Illnesses characterized by clonal
proliferation of histiocytes in various tissues were
traditionally labeled eosinophilic granuloma of bone,
Hand-Schuller-Christian syndrome, and Letterer-Siwe
disease. Lichtenstein integrated these entities under the
title histiocytosis X [1].The Histiocyte Society now
recommends the term Langerhans Cell Histiocytosis to
unify this disparate group of disorders. The staging system
proposed by Greenberger et al. [2] is applied in many
reports.
The relative rarity of LCH has meant that treatment
and outcome data have been based largely on small case
series and single case reports. No prospective controlled
studies have been performed so the choice of the most
appropriate treatment in everyday clinical practice may
be difficult. We report the case of Langerhans cell
histiocytosis in stage Ia according the staging system by
Greenberger [Table I] and review the literature of
treatment modalities in stages Ia and Ib to make
therapeutic decisions easier.
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Langarhans cell histiocytosis (LCH) is a rare disease. Bones are the most frequent site of this disorder. We report the case of
LCH of the skull in stage Ia. A 21-year-old man presented with painful, sharply demarcated, filled-in soft masses defect of the
right fronto-temporal region of the skull. The osteolytic lesion was found in this region both in plain radiograms and CT scans.
Bone scitigraphy showed increased uptake in that site. Curettage of the lesion of bone and infiltrated meninges was performed
revealing a LCH. He received post-operative radiotherapy of 12 Gy in 6 fractions. 5 years after treatment the patient is
asymptomatic, with good local control, without any signs of the dissemination of the disease.
We review the literature, present the natural course of disorder and discuss the treatment modalities and results.
Zmiany kostne w histiocytozie komórek Langerhansa
- opis przypadku i przeglàd piÊmiennictwa
Histiocytoza komórek Langerhansa (LCH) jest rzadkim, histologicznie ∏agodnym schorzeniem, którego istotà jest proliferacja
komórek Langerhansa. KoÊci sà najcz´stszà lokalizacjà zmian. W artykule przedstawiono przypadek histiocytozy w obr´bie
koÊci czaszki w stopniu zaawansowania Ia. U 21 letniego m´˝czyzny stwierdzono w prawej okolicy czo∏owo-skroniowej
bolesny, ostro odgraniczony ubytek, wype∏niony mi´kkà patologicznà masà. W wykonanym zdj´ciu RTG i KT g∏owy opisano
osteolitycznà zmian´ tego obszaru. Badanie scyntygrafii koÊçca wykaza∏o wzmo˝one gromadzenie znacznika w tym rejonie.
Wy∏y˝eczkowano nacieczonà koÊç i zaj´tà przez ciàg∏oÊç opon´ twardà. W badaniu histopatologicznym rozpoznano LCH.
Chorego napromieniono pooperacyjnie. Otrzyma∏ 12 Gy w 6 frakcjach. W 5 letnim okresie obserwacji po leczeniu stwierdzono
dobrà kontrol´ miejscowà oraz nie wykazano cech rozsiewu choroby.
W przeprowadzonym przeglàdzie piÊmiennictwa przedstawiono przebieg schorzenia oraz omówiono metody, wskazania do
leczenia oraz jego rezultaty.
Key words: histiocytosis, Langerhans cell, bone, treatment modalities
S∏owa klucze: histiocytoza, komórka Langerhansa, koÊç, metody leczenia
1 Public Hospital of Pulmonology and Oncology in Olsztyn
2 Head and Neck Department
The Maria Sk∏odowska-Curie Memorial Cancer Center
and Institute of Oncology, Warsaw, Poland
162
Case report
A 21 year-old male patient was referred to the Centre of
Oncology in September 1997. He complained of 2 months
of stubborn pain of the skull in the right fronto-temporal
region. At first this pain occurred during pressure, then it
became constant, with site- swelling. There was no history
of trauma of this region. In clinical examination a defect
of 5 cm, sharply demarcated, was palpable in the right
frontal region. The lesion was filled with soft masses. The
patient had no neurological symptoms. An osteolytic
lesion in right frontal bone was found in radiograms. A
CT scan of the head revealed a large, irregular destructive
lesion of the right frontal and partially temporal bone,
which was filled with abnormal masses. There was no
sign of brain tissue involvement. Bone scintigraphy
showed increased uptake in this region. The blood tests all
were in normal range.
Two weeks later an open biopsy with curettage of
the affected bone with part of the roof of the orbit was
performed. The infiltrated part of the meninges was also
curetted. Pathologic examination of the involved bone
by routine hematoxylin and eosin morphology revealed
Langerhans cell histiocytosis (eosinophilic granuloma –
diagnosis was confirmed by Professor Mioduszewska).
Four weeks later the patient still complained of pain in
this region and persistent disease within the meninges
was also suspected and therefore postoperative radio-
therapy was performed. The patient received a total dose
of 12 Gy to the affected area, 2 Gy per fraction, using
4 MV photons. Three-dimensional treatment planning
was used. The irradiated volume included the post-
operative bed with a 1 cm margin.
A CT scan obtained 3 months later did not show
any signs of progression, CT scans performed during
follow-up period were also normal. For 5 years now the
patient is in a good performance status, asymptomatic,
with good local control. No signs of dissemination are
observed. He has no late post- irradiation complications
and no neurological abnormalities.
Discussion
The staging system of Langerhans cell histiocytosis
proposed by Greenberger et al [2] has classified lesions
primary limited to the bone as stage Ia or Ib (Table I).
About 80% of patients show bone lesions at diagnosis
and about 40% of them have the disease limited to the
bones [3].
The lesions are benign in their histology, but with
respect to their osteolytic character lead to the destruction
of bone. LCH has a predilection for specific bones. The
flat bones are involved most frequently and among them
the skull is commonest. The other sites frequent reported
are: mandible, maxilla, femur, scapula, ribs, vertebrae,
pelvis (Table II). It remains unclear why the skull is so
favored by this disease. These tumors rarely appear in
the small bones of the hand and foot. The multifocal
form of LCH is uncommon.
Table II. Anatomic distribution and frequency 
of bone lesions in LCH
Parietal 18.1%
Frontal 9.5%
Occipital 9.5%
Temporal 7.5%
Sphenoid 2.8%
Maxilla 0.9%
Mandible 13.3%
Scapula 1.9%
Clavicle 1.9%
Humerus 2.8%
Ribs 4.7%
Spine 14.2%
Pelvis 5.7%
Femur 6.6%
Pain is the most common presenting symptom in
pediatric and adult patients. Children more commonly
develop localized soft tissue swelling than do adults. The
sharply demarcated bone defect is often palpable. Patients
with mandibular or maxillary involvement usually seek
medical attention for loose teeth and /or oral ulcers. Otitis
media and diminished hearing are common presenting
symptoms in patients with mastoid lesions. Fractures of
the affected bones can appear as a first sign of the disease.
The presented patient had typical signs of disease
but all of them are non-characteristic. Also additional
studies are non-specific for the diagnosis of LCH [4].
Bone lesion is often detected by plain-film radiography
and characterized by a lytic defect without evidence of
reactive sclerosis [3]. Biopsy of the lesion is necessary to
establish the diagnosis.
Pathology demonstrates infiltration of bone by
clusters of characteristic histiocytes with admixture of
morphologically related giant cells, eosinophils and
lymphocytes. Specific Langerhans granules (Birbec's
Table I. The staging system proposed by Greenberger et al.1981 [2]
Stage I a) Single monostotic bone lesion
b) Multiple lesions in one or multiple bone
Stage II >24 months of age at diagnosis and having one or more 
of the following systems involved: diabetes insipidus, teeth, 
gingivae, lymph nodes, skin, mild lung involvement (i.e., 
infiltrates seen on chest radiograph without pulmonary 
symptoms or gross consolidation), focally positive bone 
marrow
Stage III a) Age <24 months at diagnosis with any of the systems 
involved in stage II
b) Age >24 moths with involvement of liver and/or spleen, 
massive nodal involvement (nodes > 5 x 5 cm in several 
sites above or below diaphragm), honeycomb lung 
(major involvement in all areas with apparent fibrosis), 
bone marrow packed
Stage IV Spleen > 6 cm (palpable below costal margin) and fever >1
month with or without any or all of the above systems 
involved
Stage V "Special" monocytosis in peripheral blood > 20% of 
differential cell count, in addition to stage III or IV
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granules) can be identified in the histiocytes by electron
microscopy. Immunohistichemistry shows strong S-100
protein, HLA-DR and CD-1a surface antigen positivity by
the histiocytosis X cells [5, 6]. The necessity of the
immunohistochemisty or ultrastructural examination for
the diagnosis of LCH is controversial. Many authors
believe that definitive diagnosis can be established by
routine hematoxylin and eosin morphology especially
when correlated with radiological and clinical data [8].
When immunohistochemistry or ulrastructural analysis
is used as definitive tool for establishing a pathologic
diagnosis it can lead to misdiagnosis [7, 8]. Use of the
histopathologic parameters to predict prognosis in LCH
has produced conflicting results. Some studies report
significant eosinophilia as a favorable prognostic indicator
[9] but the others show no feature correlated with survival
[4].
The treatment of LCH is usually reserved for the
patients with symptomatic lesions [10]. Asymptomatic
patients should be observed because some lesions
appeared to resolve spontaneously [11, 12]. The lesion
responds well to the most treatment modalities e.g.
curettage, excision, irradiation and infrequently resulted
in functional impairment [13-20]. Therapeutic strategy
depends on the size, localization of the lesion and age of
the patient. There is no objective indication that the kind
of therapy effectively altered the course of disorder or
prevented its progression [3, 4, 21].
The generally accepted treatment of choice for
solitary bone lesions, especially for these affecting
calvaria, is surgical excision when the lesion is readily
accessible. Data of many authors indicate that surgical
curettage is a very successful treatment. If necessary,
excision is combined with concurrent bone grafting.
However some authors report the higher risk of local
recurrence after surgery alone [2, 22]. Persistence
symptoms of disease, or expansion of the lesion after
surgical intervention, may respond to the subsequent
radiotherapy [23]. In presented case we doubted whether
curettage of the meninges was a sufficient procedure,
while the persistent pain was also alarming. For these
reasons it was decided that surgery should be followed by
irradiation.
Primary radiotherapy in LCH of bone is recom-
mended in the following cases: symptomatic, with lesions
large in size, with strong pain, potential for fracture,
multifocal in one bone and in circumstances in which
surgical resection might result in significant functional
or health risk [3, 13, 16,18-20, 23-25]. Modern radiation
modalities, such as stereotactic radiotherapy, can be
useful especially in cases with intracranial base lesions if
there is incomplete resolution of the symptoms after
sterotactic biopsy or during recurrence [26-27]. This
method allows to use sufficient doses of radiation to the
target volume with sufficient precision to avoid vital
structures at cranial base. Because there are no large
prospective series with adequate follow-ups on the
effectiveness or possible complications of stereotactic
radiotherapy for this lesion such a modality must be used
cautiously, especially in children.
Doses of radiotherapy recommended in literature
range from 2 Gy to 30 Gy in conventional fractionation
schedule [2, 18, 24, 25, 28]. Greenberger et al. report
95% local control using total dose 4-20 Gy [25, 28].
Similar results are reported by Anonsen et al. [24] where
total doses of 6-20 Gy allow to obtain a local control of 88
%. According to these reports we delivered 12 Gy to the
surgical bed. Acc. to some authors [3, 13, 16] the dose of
radiotherapy depends on the age of the patient. In the
group under 10 years of age it has been observed that
lesions are very radiosensitive and the recommended dose
range from 6-10 Gy. It is also reported that patients aged
over 18 do not achieve such good results of radiotherapy
as children (local control 72 % vs 100 %, respectively).
The total dose in this group of the patients should be
over 20 Gy, but in these reports the number of reported
adult cases was very small and the results have not been
confirmed by other investigators on larger number of the
patients [4].
The morbidity of radiation therapy is rather slight
because of the low dose of irradiation but in the child
group it is extremely important to remember that
disturbances in bone growth are observed [11, 13]. Also
cases of scoliosis are described after radiotherapy of the
vertebral column. It is difficult to state whether this
complication is associated with irradiation or with surgery
or both [13]. Some authors report secondary malignances
in field, related with low dose of radiotherapy [29]. In
the reported case we do not observed any late effects of
radiotherapy.
The treatment of LCH primary limited to the bone
with chemotherapy is associated with poor results (only
25% responders) and after this adjuvant radiotherapy is
recommended in normal doses [30, 31]. Chemotherapy
based on multidrug programs is used rather for
disseminated disease or in cases with recurrent disease
with progression from solitary to multifocal bone lesions
[18, 29]. Recent literature supports the idea that steroid
injection with 50-150 mg of methylprednisolon is effective
in the management of recurrent or expansive lesions [32,
33].
Results of treatment are good. Local control of 85-
100% of bone lesions and overall survivals of 90-100%
after radiotherapy or surgery is reported with a median
follow-up of 10 years [3, 13, 18, 29]. Control of the bone
lesions required: resolution of pain, absence of uptake
on radionuclide scan and reconstruction of bone shadow
on plain radiography. Reports in the literature [23, 33]
describe post irradiation bony healing at an average 8
months (range 6-34 months).
Prognosis in LCH is different in relation to the
extension of the disease and is favorable with only one site
of the disease and in patients over 2 years of age, while it
is the best in patients with solitary bone lesions [4, 18].
Kilpatrick et al. report that even in case of multifocal
bone lesions some 80% of patients achieve long disease
free survival after treatment but they have a higher risk of
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internal organ involvement in the future [4, 18, 34]. The
presented patient remains in the most favorable group,
however in adults new bone lesions appear more
frequently (15%) than in children (5%) during the follow-
up period [4]. Most of the skeletal recurrences occur
within 2 years of the previous diagnosis. The jaw and
mastoid bones are the most common sites of skeletal
recurrences. The interval between the original diagnosis
and recurrence ranged from 2 months to 13 years, also
completely new bone lesions, solitary or multiple, can
occur from 1 month to 33 years. Because of that long-
term follow-up is recommended in LCH [13, 18, 19]. The
5-year follow-up free of recurrence in our case is
insufficient to state that the patient is already cured.
Several authors [23, 35] have reported excellent results
when a second course of irradiation is applied to
recurrent or persistent bone lesions, but in those series
the initial dose was inadequate. Others [12] maintain that
re-irradiation proved to be of little benefit. Progression
from Ia and Ib stage to the disseminated disease is
observed in 30% of the patients.
Conclusion
The treatment result of the presented case of LCH of
bone is good in a 5-year follow-up, but long-term follow-
up is necessary. Although the bone lesions in LCH
respond well to most treatment methods, optimal therapy
is still unknown because no prospective controlled study
has been performed. No current modality treatment does
effectively alter the course of the disorder or prevents its
progression.
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